drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01041 | DB01118 | 770 | 33 | [
"DDInter1789",
"DDInter76"
] | Thalidomide | Amiodarone | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
770,
24,
33
]
],
[
[
770,
24,
540
],
[
540,
1,
33
]
],
[
[
770,
6,
7950
],
[
7950,
45,
33
]
],
[
[
770,
7,
7669
],
[
7669,
46,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Thalidomide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound)
Thalidomide (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gen... |
DB09312 | DB14711 | 967 | 779 | [
"DDInter103",
"DDInter1680"
] | Antilymphocyte immunoglobulin (horse) | Smallpox (Vaccinia) Vaccine, Live | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
967,
25,
779
]
],
[
[
967,
64,
1064
],
[
1064,
25,
779
]
],
[
[
967,
25,
1259
],
[
1259,
25,
779
]
],
[
[
967,
24,
270
],
[
270,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when take... | Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when ... |
DB06016 | DB06655 | 1,508 | 5 | [
"DDInter300",
"DDInter1077"
] | Cariprazine | Liraglutide | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1508,
24,
5
]
],
[
[
1508,
63,
353
],
[
353,
23,
5
]
],
[
[
1508,
63,
245
],
[
245,
24,
5
]
],
[
[
1508,
24,
1296
],
[
1296,
63,... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and ... |
DB00960 | DB06709 | 887 | 592 | [
"DDInter1471",
"DDInter1165"
] | Pindolol | Methacholine | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing symptoms such as difficulty breathing.[A229598, A229603] Although the underlying patholo... | Major | 2 | [
[
[
887,
25,
592
]
],
[
[
887,
21,
28644
],
[
28644,
60,
592
]
],
[
[
887,
1,
668
],
[
668,
25,
592
]
],
[
[
887,
40,
1121
],
[
1121,
... | [
[
[
"Pindolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methacholine"
]
],
[
[
"Pindolol",
"{u} (Compound) causes {v} (Side Effect)",
"Syncope"
],
[
"Syncope",
"{u} (Side Effect) is caused by {v} (Compound)"... | Pindolol (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Methacholine (Compound)
Pindolol (Compound) resembles Levobunolol (Compound) and Levobunolol may lead to a major life threatening interaction when taken with Methacholine
Pindolol (Compound) resembles Bisoprolol (Compound) and Bisop... |
DB01001 | DB01222 | 688 | 617 | [
"DDInter1632",
"DDInter246"
] | Salbutamol | Budesonide | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Minor | 0 | [
[
[
688,
23,
617
]
],
[
[
688,
62,
1351
],
[
1351,
1,
617
]
],
[
[
688,
23,
1220
],
[
1220,
1,
617
]
],
[
[
688,
5,
11649
],
[
11649,
... | [
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flunisolide"
],
[
... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Flunisolide and Flunisolide (Compound) resembles Budesonide (Compound)
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Compou... |
DB00635 | DB05679 | 1,573 | 1,683 | [
"DDInter1515",
"DDInter1907"
] | Prednisone | Ustekinumab | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1573,
24,
1683
]
],
[
[
1573,
62,
1461
],
[
1461,
23,
1683
]
],
[
[
1573,
23,
1193
],
[
1193,
62,
1683
]
],
[
[
1573,
24,
1129
],
[
11... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Prednisone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Prednisone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluc... |
DB01611 | DB11057 | 1,487 | 720 | [
"DDInter893",
"DDInter1223"
] | Hydroxychloroquine | Mineral oil | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1487,
24,
720
]
],
[
[
1487,
25,
927
],
[
927,
63,
720
]
],
[
[
1487,
64,
1151
],
[
1151,
24,
720
]
],
[
[
1487,
25,
1069
],
[
1069,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[... | Hydroxychloroquine may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Hydroxychloroquine may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may caus... |
DB01033 | DB06688 | 328 | 1,430 | [
"DDInter1156",
"DDInter1677"
] | Mercaptopurine | Sipuleucel-T | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
328,
24,
1430
]
],
[
[
328,
63,
51
],
[
51,
24,
1430
]
],
[
[
328,
25,
676
],
[
676,
63,
1430
]
],
[
[
328,
24,
1531
],
[
1531,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Mercaptopurine may lead to a major life threatening interaction when taken with Upadacitinib and Upada... |
DB00836 | DB06595 | 543 | 1,491 | [
"DDInter1088",
"DDInter1214"
] | Loperamide | Midostaurin | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
543,
24,
1491
]
],
[
[
543,
24,
112
],
[
112,
23,
1491
]
],
[
[
543,
63,
888
],
[
888,
24,
1491
]
],
[
[
543,
24,
1342
],
[
1342,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Ta... |
DB00647 | DB06589 | 675 | 1,250 | [
"DDInter528",
"DDInter1400"
] | Dextropropoxyphene | Pazopanib | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
675,
24,
1250
]
],
[
[
675,
6,
3486
],
[
3486,
45,
1250
]
],
[
[
675,
7,
5178
],
[
5178,
46,
1250
]
],
[
[
675,
21,
28658
],
[
28658,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {... | Dextropropoxyphene (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pazopanib (Compound)
Dextropropoxyphene (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is upregulated by Pazopanib (Compound)
Dextropropoxyphene (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib ... |
DB00488 | DB01041 | 196 | 770 | [
"DDInter57",
"DDInter1789"
] | Altretamine | Thalidomide | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
196,
25,
770
]
],
[
[
196,
21,
28784
],
[
28784,
60,
770
]
],
[
[
196,
24,
4
],
[
4,
63,
770
]
],
[
[
196,
63,
288
],
[
288,
24,... | [
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is ca... | Altretamine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Thalidomide (Compound)
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that co... |
DB00647 | DB00912 | 675 | 473 | [
"DDInter528",
"DDInter1581"
] | Dextropropoxyphene | Repaglinide | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
675,
24,
473
]
],
[
[
675,
6,
3486
],
[
3486,
45,
473
]
],
[
[
675,
21,
28757
],
[
28757,
60,
473
]
],
[
[
675,
63,
73
],
[
73,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by... | Dextropropoxyphene (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Dextropropoxyphene (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Repaglinide (Compound)
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when take... |
DB00843 | DB00945 | 479 | 1,479 | [
"DDInter583",
"DDInter20"
] | Donepezil | Acetylsalicylic acid | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Minor | 0 | [
[
[
479,
23,
1479
]
],
[
[
479,
7,
2900
],
[
2900,
45,
1479
]
],
[
[
479,
6,
6017
],
[
6017,
45,
1479
]
],
[
[
479,
21,
28931
],
[
28931,
... | [
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Donepezil",
"{u} (Compound) upregulates {v} (Gene)",
"NFKBIA"
],
[
"NFKBIA",
"{u} (Gene) is bound by {v} ... | Donepezil (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is bound by Acetylsalicylic acid (Compound)
Donepezil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Acetylsalicylic acid (Compound)
Donepezil (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Acetylsalic... |
DB08904 | DB12240 | 375 | 110 | [
"DDInter342",
"DDInter1485"
] | Certolizumab pegol | Polatuzumab vedotin | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Major | 2 | [
[
[
375,
25,
110
]
],
[
[
375,
63,
467
],
[
467,
24,
110
]
],
[
[
375,
64,
1419
],
[
1419,
24,
110
]
],
[
[
375,
25,
951
],
[
951,
2... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
... | Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Certolizumab pegol may lead to a major life threatening interaction when taken with Imatinib ... |
DB00514 | DB00909 | 506 | 306 | [
"DDInter527",
"DDInter1971"
] | Dextromethorphan | Zonisamide | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Moderate | 1 | [
[
[
506,
24,
306
]
],
[
[
506,
6,
8374
],
[
8374,
45,
306
]
],
[
[
506,
21,
28691
],
[
28691,
60,
306
]
],
[
[
506,
24,
1609
],
[
1609,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} ... | Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zonisamide (Compound)
Dextromethorphan (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Zonisamide (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00867 | DB06663 | 1,052 | 1,154 | [
"DDInter1606",
"DDInter1398"
] | Ritodrine | Pasireotide | Adrenergic beta-agonist used to control premature labor. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1052,
25,
1154
]
],
[
[
1052,
24,
1385
],
[
1385,
63,
1154
]
],
[
[
1052,
24,
170
],
[
170,
24,
1154
]
],
[
[
1052,
63,
1647
],
[
1647... | [
[
[
"Ritodrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutid... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sita... |
DB00317 | DB08880 | 883 | 1,510 | [
"DDInter810",
"DDInter1771"
] | Gefitinib | Teriflunomide | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
883,
25,
1510
]
],
[
[
883,
24,
129
],
[
129,
63,
1510
]
],
[
[
883,
24,
697
],
[
697,
24,
1510
]
],
[
[
883,
24,
1622
],
[
1622,
... | [
[
[
"Gefitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalut... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital an... |
DB00011 | DB01030 | 1,451 | 869 | [
"DDInter944",
"DDInter1835"
] | Interferon alfa-n1 | Topotecan | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
1451,
24,
869
]
],
[
[
1451,
24,
310
],
[
310,
63,
869
]
],
[
[
1451,
24,
482
],
[
482,
24,
869
]
],
[
[
1451,
25,
1064
],
[
1064,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Tiog... |
DB00022 | DB00352 | 268 | 482 | [
"DDInter1408",
"DDInter1814"
] | Peginterferon alfa-2b | Tioguanine | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
268,
24,
482
]
],
[
[
268,
24,
1439
],
[
1439,
63,
482
]
],
[
[
268,
24,
912
],
[
912,
24,
482
]
],
[
[
268,
63,
1257
],
[
1257,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipili... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00087 | DB00307 | 599 | 1,101 | [
"DDInter41",
"DDInter202"
] | Alemtuzumab | Bexarotene | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Moderate | 1 | [
[
[
599,
24,
1101
]
],
[
[
599,
24,
597
],
[
597,
62,
1101
]
],
[
[
599,
24,
168
],
[
168,
23,
1101
]
],
[
[
599,
63,
1253
],
[
1253,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib ... |
DB08871 | DB11796 | 36 | 1,612 | [
"DDInter666",
"DDInter786"
] | Eribulin | Fostemsavir | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
36,
24,
1612
]
],
[
[
36,
63,
112
],
[
112,
23,
1612
]
],
[
[
36,
63,
1424
],
[
1424,
24,
1612
]
],
[
[
36,
24,
823
],
[
823,
63... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine ... |
DB01044 | DB08899 | 246 | 129 | [
"DDInter809",
"DDInter649"
] | Gatifloxacin | Enzalutamide | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
246,
25,
129
]
],
[
[
246,
25,
918
],
[
918,
1,
129
]
],
[
[
246,
6,
1829
],
[
1829,
45,
129
]
],
[
[
246,
21,
28703
],
[
28703,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
... | Gatifloxacin may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Gatifloxacin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Enzalutamide (Compound)
Gatifloxacin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Ef... |
DB00227 | DB12941 | 1,463 | 466 | [
"DDInter1098",
"DDInter481"
] | Lovastatin | Darolutamide | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
1463,
24,
466
]
],
[
[
1463,
64,
600
],
[
600,
23,
466
]
],
[
[
1463,
24,
351
],
[
351,
23,
466
]
],
[
[
1463,
24,
159
],
[
159,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Lovastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Flucona... | Lovastatin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may caus... |
DB00580 | DB00877 | 311 | 629 | [
"DDInter1910",
"DDInter1678"
] | Valdecoxib | Sirolimus | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
311,
25,
629
]
],
[
[
311,
24,
1476
],
[
1476,
63,
629
]
],
[
[
311,
24,
167
],
[
167,
24,
629
]
],
[
[
311,
63,
1645
],
[
1645,
... | [
[
[
"Valdecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib"... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hyd... |
DB00083 | DB00424 | 677 | 19 | [
"DDInter225",
"DDInter896"
] | Botulinum toxin type A | Hyoscyamine | In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperf... | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Moderate | 1 | [
[
[
677,
24,
19
]
],
[
[
677,
24,
85
],
[
85,
63,
19
]
],
[
[
677,
24,
701
],
[
701,
24,
19
]
],
[
[
677,
24,
85
],
[
85,
1,
1... | [
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"At... | Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00687 | DB04574 | 870 | 177 | [
"DDInter747",
"DDInter684"
] | Fludrocortisone | Estrone sulfate (topical) | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Estrone 3-sulfate is a steroid sulfate that is the 3-sulfate of estrone. It has a role as a human metabolite and a mouse metabolite. It is a 17-oxo steroid and a steroid sulfate. It is functionally related to an estrone. It is a conjugate acid of an estrone 3-sulfate(1-). It derives from a hydride of an estrane. | Moderate | 1 | [
[
[
870,
24,
177
]
],
[
[
870,
63,
380
],
[
380,
1,
177
]
],
[
[
870,
24,
35
],
[
35,
1,
177
]
],
[
[
870,
21,
28748
],
[
28748,
60,... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone sulfate"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated e... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estrone sulfate (Compound)
Fludrocortisone ma... |
DB11827 | DB11943 | 433 | 255 | [
"DDInter669",
"DDInter495"
] | Ertugliflozin | Delafloxacin | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
433,
24,
255
]
],
[
[
433,
24,
1476
],
[
1476,
63,
255
]
],
[
[
433,
63,
417
],
[
417,
24,
255
]
],
[
[
433,
63,
1411
],
[
1411,
... | [
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate an... |
DB00468 | DB00557 | 1,424 | 252 | [
"DDInter1557",
"DDInter895"
] | Quinine | Hydroxyzine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Moderate | 1 | [
[
[
1424,
24,
252
]
],
[
[
1424,
24,
851
],
[
851,
1,
252
]
],
[
[
1424,
24,
623
],
[
623,
40,
252
]
],
[
[
1424,
6,
12523
],
[
12523,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
"... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Hydroxyzine (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Hydroxyzine (Compound)
Quin... |
DB00196 | DB09073 | 600 | 951 | [
"DDInter743",
"DDInter1379"
] | Fluconazole | Palbociclib | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
600,
24,
951
]
],
[
[
600,
23,
907
],
[
907,
62,
951
]
],
[
[
600,
25,
318
],
[
318,
23,
951
]
],
[
[
600,
23,
271
],
[
271,
23,... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Fluconazole may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cau... |
DB01132 | DB01357 | 1,130 | 890 | [
"DDInter1472",
"DDInter1160"
] | Pioglitazone | Mestranol | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Minor | 0 | [
[
[
1130,
23,
890
]
],
[
[
1130,
62,
1197
],
[
1197,
40,
890
]
],
[
[
1130,
24,
35
],
[
35,
40,
890
]
],
[
[
1130,
63,
380
],
[
380,
... | [
[
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mestranol"
]
],
[
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norethisterone"
],
[... | Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norethisterone and Norethisterone (Compound) resembles Mestranol (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Mestranol (Co... |
DB09039 | DB14840 | 1,670 | 861 | [
"DDInter629",
"DDInter1601"
] | Eliglustat | Ripretinib | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
1670,
24,
861
]
],
[
[
1670,
25,
351
],
[
351,
24,
861
]
],
[
[
1670,
24,
214
],
[
214,
24,
861
]
],
[
[
1670,
63,
353
],
[
353,
... | [
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib... | Eliglustat may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may ca... |
DB00696 | DB14568 | 826 | 982 | [
"DDInter665",
"DDInter1000"
] | Ergotamine | Ivosidenib | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
826,
24,
982
]
],
[
[
826,
63,
1101
],
[
1101,
23,
982
]
],
[
[
826,
40,
628
],
[
628,
24,
982
]
],
[
[
826,
24,
1478
],
[
1478,
... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Ergotamine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that could... |
DB06016 | DB14568 | 1,508 | 982 | [
"DDInter300",
"DDInter1000"
] | Cariprazine | Ivosidenib | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1508,
24,
982
]
],
[
[
1508,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1508,
63,
770
],
[
770,
24,
982
]
],
[
[
1508,
24,
1478
],
[
1478,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thali... |
DB00108 | DB00928 | 1,066 | 1,426 | [
"DDInter1268",
"DDInter148"
] | Natalizumab | Azacitidine | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Major | 2 | [
[
[
1066,
25,
1426
]
],
[
[
1066,
25,
1238
],
[
1238,
40,
1426
]
],
[
[
1066,
25,
372
],
[
372,
1,
1426
]
],
[
[
1066,
25,
1064
],
[
1064,... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azacitidine"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"... | Natalizumab may lead to a major life threatening interaction when taken with Pentostatin and Pentostatin (Compound) resembles Azacitidine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine (Compound) resembles Azacitidine (Compound)
Natalizumab may lead t... |
DB00983 | DB12161 | 480 | 730 | [
"DDInter776",
"DDInter512"
] | Formoterol | Deutetrabenazine | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
480,
24,
730
]
],
[
[
480,
63,
322
],
[
322,
24,
730
]
],
[
[
480,
24,
971
],
[
971,
24,
730
]
],
[
[
480,
24,
1619
],
[
1619,
6... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib an... |
DB00258 | DB00978 | 666 | 739 | [
"DDInter270",
"DDInter1084"
] | Calcium acetate | Lomefloxacin | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
666,
24,
739
]
],
[
[
666,
24,
945
],
[
945,
40,
739
]
],
[
[
666,
63,
1176
],
[
1176,
1,
739
]
],
[
[
666,
24,
1299
],
[
1299,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lo... |
DB01177 | DB01227 | 77 | 1,301 | [
"DDInter904",
"DDInter1043"
] | Idarubicin | Levacetylmethadol | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Major | 2 | [
[
[
77,
25,
1301
]
],
[
[
77,
64,
494
],
[
494,
1,
1301
]
],
[
[
77,
63,
675
],
[
675,
1,
1301
]
],
[
[
77,
62,
112
],
[
112,
23,
... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
... | Idarubicin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Levacetylm... |
DB05239 | DB05273 | 866 | 507 | [
"DDInter425",
"DDInter1638"
] | Cobimetinib | Samarium (153Sm) lexidronam | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
866,
25,
507
]
],
[
[
866,
63,
248
],
[
248,
24,
507
]
],
[
[
866,
24,
270
],
[
270,
63,
507
]
],
[
[
866,
63,
1101
],
[
1101,
2... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken... |
DB00584 | DB01284 | 610 | 1,042 | [
"DDInter638",
"DDInter1782"
] | Enalapril | Tetracosactide | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
610,
24,
1042
]
],
[
[
610,
24,
761
],
[
761,
63,
1042
]
],
[
[
610,
24,
1144
],
[
1144,
24,
1042
]
],
[
[
610,
40,
1638
],
[
1638,
... | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[... | Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and N... |
DB09078 | DB11718 | 1,228 | 927 | [
"DDInter1036",
"DDInter640"
] | Lenvatinib | Encorafenib | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1228,
24,
927
]
],
[
[
1228,
62,
112
],
[
112,
23,
927
]
],
[
[
1228,
24,
720
],
[
720,
24,
927
]
],
[
[
1228,
63,
216
],
[
216,
... | [
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lenvatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mi... |
DB00366 | DB00486 | 1,594 | 1,614 | [
"DDInter600",
"DDInter1253"
] | Doxylamine | Nabilone | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1594,
24,
1614
]
],
[
[
1594,
24,
530
],
[
530,
1,
1614
]
],
[
[
1594,
21,
28769
],
[
28769,
60,
1614
]
],
[
[
1594,
24,
999
],
[
999,... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Doxylamine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Nabilone (Compound)
Doxylamine may cause a moderate in... |
DB00570 | DB12500 | 147 | 283 | [
"DDInter1936",
"DDInter714"
] | Vinblastine | Fedratinib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
147,
24,
283
]
],
[
[
147,
24,
351
],
[
351,
23,
283
]
],
[
[
147,
24,
1339
],
[
1339,
62,
283
]
],
[
[
147,
24,
327
],
[
327,
2... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Bero... |
DB00497 | DB01246 | 828 | 820 | [
"DDInter1366",
"DDInter45"
] | Oxycodone | Alimemazine | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
828,
24,
820
]
],
[
[
828,
24,
104
],
[
104,
40,
820
]
],
[
[
828,
24,
401
],
[
401,
24,
820
]
],
[
[
828,
24,
649
],
[
649,
1,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB06701 | DB08824 | 1,177 | 591 | [
"DDInter521",
"DDInter959"
] | Dexmethylphenidate | Ioflupane I-123 | Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer s... | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
1177,
24,
591
]
],
[
[
1177,
6,
2437
],
[
2437,
45,
591
]
],
[
[
1177,
21,
28734
],
[
28734,
60,
591
]
],
[
[
1177,
40,
895
],
[
895,
... | [
[
[
"Dexmethylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Dexmethylphenidate",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is boun... | Dexmethylphenidate (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Ioflupane I-123 (Compound)
Dexmethylphenidate (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Ioflupane I-123 (Compound)
Dexmethylphenidate (Compound) resembles Methylphenidate (C... |
DB00910 | DB00999 | 1,041 | 504 | [
"DDInter1394",
"DDInter883"
] | Paricalcitol | Hydrochlorothiazide | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Moderate | 1 | [
[
[
1041,
24,
504
]
],
[
[
1041,
24,
178
],
[
178,
1,
504
]
],
[
[
1041,
63,
323
],
[
323,
40,
504
]
],
[
[
1041,
24,
674
],
[
674,
... | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
... | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compoun... |
DB01191 | DB06779 | 1,039 | 365 | [
"DDInter518",
"DDInter470"
] | Dexfenfluramine | Dalteparin | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Moderate | 1 | [
[
[
1039,
24,
365
]
],
[
[
1039,
64,
1100
],
[
1100,
24,
365
]
],
[
[
1039,
25,
1427
],
[
1427,
63,
365
]
],
[
[
1039,
25,
901
],
[
901,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
... | Dexfenfluramine may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Dexfenfluramine may lead to a major life threatening interaction when taken with Vortioxetine and Vortioxetine may cause... |
DB00687 | DB00960 | 870 | 887 | [
"DDInter747",
"DDInter1471"
] | Fludrocortisone | Pindolol | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Moderate | 1 | [
[
[
870,
24,
887
]
],
[
[
870,
24,
819
],
[
819,
40,
887
]
],
[
[
870,
23,
1148
],
[
1148,
63,
887
]
],
[
[
870,
63,
88
],
[
88,
40,... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction ... |
DB00434 | DB00962 | 13 | 1,639 | [
"DDInter459",
"DDInter1957"
] | Cyproheptadine | Zaleplon | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Moderate | 1 | [
[
[
13,
24,
1639
]
],
[
[
13,
21,
29544
],
[
29544,
60,
1639
]
],
[
[
13,
24,
1609
],
[
1609,
63,
1639
]
],
[
[
13,
63,
1242
],
[
1242,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Weight increased"
],
[
"Weight increased",
"{u} (... | Cyproheptadine (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Zaleplon (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseas... |
DB01149 | DB12010 | 851 | 214 | [
"DDInter1274",
"DDInter785"
] | Nefazodone | Fostamatinib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Major | 2 | [
[
[
851,
25,
214
]
],
[
[
851,
25,
976
],
[
976,
24,
214
]
],
[
[
851,
63,
723
],
[
723,
24,
214
]
],
[
[
851,
24,
973
],
[
973,
24,... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{... | Nefazodone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may ca... |
DB00662 | DB00844 | 717 | 314 | [
"DDInter1873",
"DDInter1257"
] | Trimethobenzamide | Nalbuphine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
717,
24,
314
]
],
[
[
717,
63,
828
],
[
828,
40,
314
]
],
[
[
717,
63,
421
],
[
421,
1,
314
]
],
[
[
717,
63,
475
],
[
475,
25,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalb... |
DB00372 | DB00934 | 999 | 413 | [
"DDInter1793",
"DDInter1124"
] | Thiethylperazine | Maprotiline | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Moderate | 1 | [
[
[
999,
24,
413
]
],
[
[
999,
63,
1302
],
[
1302,
40,
413
]
],
[
[
999,
24,
22
],
[
22,
62,
413
]
],
[
[
999,
24,
103
],
[
103,
63,... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a minor interact... |
DB00810 | DB00836 | 456 | 543 | [
"DDInter211",
"DDInter1088"
] | Biperiden | Loperamide | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
456,
24,
543
]
],
[
[
456,
24,
649
],
[
649,
1,
543
]
],
[
[
456,
63,
262
],
[
262,
24,
543
]
],
[
[
456,
1,
11268
],
[
11268,
4... | [
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Loperamide (Compound)
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exa... |
DB09049 | DB12130 | 1,135 | 1,017 | [
"DDInter1261",
"DDInter1094"
] | Naloxegol | Lorlatinib | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1135,
24,
1017
]
],
[
[
1135,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1135,
62,
409
],
[
409,
24,
1017
]
],
[
[
1135,
64,
984
],
[
984,
... | [
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Felodipine and Felodipine m... |
DB01101 | DB08868 | 60 | 1,011 | [
"DDInter285",
"DDInter737"
] | Capecitabine | Fingolimod | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
60,
25,
1011
]
],
[
[
60,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
60,
63,
112
],
[
112,
23,
1011
]
],
[
[
60,
24,
748
],
[
748,
... | [
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Capecitabine",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side Effect) is cause... | Capecitabine (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when ... |
DB00445 | DB08827 | 322 | 990 | [
"DDInter655",
"DDInter1085"
] | Epirubicin | Lomitapide | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
322,
24,
990
]
],
[
[
322,
21,
28701
],
[
28701,
60,
990
]
],
[
[
322,
24,
1362
],
[
1362,
63,
990
]
],
[
[
322,
35,
77
],
[
77,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is ca... | Epirubicin (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Lomitapide (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapid... |
DB01050 | DB11793 | 848 | 738 | [
"DDInter900",
"DDInter1297"
] | Ibuprofen | Niraparib | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
848,
24,
738
]
],
[
[
848,
25,
1213
],
[
1213,
24,
738
]
],
[
[
848,
24,
1033
],
[
1033,
63,
738
]
],
[
[
848,
64,
663
],
[
663,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Ibuprofen may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moder... |
DB00515 | DB14115 | 589 | 1,312 | [
"DDInter387",
"DDInter868"
] | Cisplatin | Human botulinum neurotoxin A/B immune globulin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle t... | Major | 2 | [
[
[
589,
25,
1312
]
],
[
[
589,
24,
123
],
[
123,
24,
1312
]
],
[
[
589,
24,
1132
],
[
1132,
25,
1312
]
],
[
[
589,
25,
629
],
[
629,
... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human botulinum neurotoxin A/B immune globulin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatid... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Human botulinum neurotoxin A/B immune globulin
Cisplatin may cause a moderate interaction that could exacerbate diseases when ... |
DB00762 | DB01144 | 613 | 1,326 | [
"DDInter973",
"DDInter540"
] | Irinotecan | Diclofenamide | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
613,
24,
1326
]
],
[
[
613,
24,
504
],
[
504,
1,
1326
]
],
[
[
613,
24,
359
],
[
359,
40,
1326
]
],
[
[
613,
7,
2789
],
[
2789,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) res... |
DB00342 | DB12161 | 1,181 | 730 | [
"DDInter1770",
"DDInter512"
] | Terfenadine | Deutetrabenazine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
1181,
24,
730
]
],
[
[
1181,
23,
112
],
[
112,
23,
730
]
],
[
[
1181,
24,
322
],
[
322,
24,
730
]
],
[
[
1181,
63,
521
],
[
521,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin ... |
DB00341 | DB01142 | 1,242 | 1,264 | [
"DDInter343",
"DDInter593"
] | Cetirizine | Doxepin | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1242,
24,
1264
]
],
[
[
1242,
24,
508
],
[
508,
24,
1264
]
],
[
[
1242,
40,
11296
],
[
11296,
40,
1264
]
],
[
[
1242,
24,
649
],
[
649... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Cetirizine (Compound) resembles Bromodiphenhydramine (Compound) and Bromodiphenhydramine (Compound) resembles Doxepin... |
DB00377 | DB04896 | 1,494 | 901 | [
"DDInter1382",
"DDInter1220"
] | Palonosetron | Milnacipran | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Major | 2 | [
[
[
1494,
25,
901
]
],
[
[
1494,
25,
41
],
[
41,
1,
901
]
],
[
[
1494,
25,
1349
],
[
1349,
40,
901
]
],
[
[
1494,
21,
29269
],
[
29269,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran... | Palonosetron may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Milnacipran (Compound)
Palonosetron (... |
DB01149 | DB01246 | 851 | 820 | [
"DDInter1274",
"DDInter45"
] | Nefazodone | Alimemazine | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
851,
24,
820
]
],
[
[
851,
1,
11237
],
[
11237,
40,
820
]
],
[
[
851,
63,
401
],
[
401,
24,
820
]
],
[
[
851,
24,
649
],
[
649,
... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Acetophenazine"
],
[
"Acetophenazine",
"{u} (Compound)... | Nefazodone (Compound) resembles Acetophenazine (Compound) and Acetophenazine (Compound) resembles Alimemazine (Compound)
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00363 | DB00377 | 695 | 1,494 | [
"DDInter419",
"DDInter1382"
] | Clozapine | Palonosetron | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Major | 2 | [
[
[
695,
25,
1494
]
],
[
[
695,
6,
17589
],
[
17589,
45,
1494
]
],
[
[
695,
23,
112
],
[
112,
62,
1494
]
],
[
[
695,
25,
1148
],
[
1148,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"HTR3A"
],
[
"HTR3A",
"{u} (Gene) is bound by {v} (Compound)",
"Palonoset... | Clozapine (Compound) binds HTR3A (Gene) and HTR3A (Gene) is bound by Palonosetron (Compound)
Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Palonosetron
Clozapine may le... |
DB01276 | DB06791 | 123 | 1,446 | [
"DDInter706",
"DDInter1021"
] | Exenatide | Lanreotide | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
123,
24,
1446
]
],
[
[
123,
24,
154
],
[
154,
63,
1446
]
],
[
[
123,
63,
1685
],
[
1685,
24,
1446
]
],
[
[
123,
24,
1254
],
[
1254,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insul... |
DB00682 | DB00991 | 126 | 97 | [
"DDInter1951",
"DDInter1358"
] | Warfarin | Oxaprozin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Major | 2 | [
[
[
126,
36,
97
]
],
[
[
126,
63,
362
],
[
362,
1,
97
]
],
[
[
126,
36,
1274
],
[
1274,
24,
97
]
],
[
[
126,
35,
307
],
[
307,
1,
... | [
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phe... | Warfarin (Compound) resembles Oxaprozin (Compound) and
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Oxaprozin (Compound)
Warfarin (Compound) resembles Flurbiprofen (Compound) and Warfarin may lead to a major life threatening intera... |
DB08903 | DB09080 | 996 | 144 | [
"DDInter170",
"DDInter1331"
] | Bedaquiline | Olodaterol | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
996,
24,
144
]
],
[
[
996,
64,
1011
],
[
1011,
24,
144
]
],
[
[
996,
75,
11
],
[
11,
24,
144
]
],
[
[
996,
63,
543
],
[
543,
24,... | [
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolim... | Bedaquiline may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Bedaquiline (Compound) resembles Toremifene (Compound) and Bedaquiline may lead to a major life threatening interaction when t... |
DB00063 | DB00682 | 366 | 126 | [
"DDInter659",
"DDInter1951"
] | Eptifibatide | Warfarin | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
366,
25,
126
]
],
[
[
366,
23,
944
],
[
944,
62,
126
]
],
[
[
366,
24,
477
],
[
477,
62,
126
]
],
[
[
366,
24,
557
],
[
557,
63,... | [
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Eptifibatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",... | Eptifibatide may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Warfarin
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol... |
DB00531 | DB00912 | 450 | 473 | [
"DDInter456",
"DDInter1581"
] | Cyclophosphamide | Repaglinide | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
450,
24,
473
]
],
[
[
450,
6,
3486
],
[
3486,
45,
473
]
],
[
[
450,
21,
28763
],
[
28763,
60,
473
]
],
[
[
450,
63,
798
],
[
798,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v}... | Cyclophosphamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Cyclophosphamide (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Repaglinide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00407 | DB06228 | 202 | 792 | [
"DDInter115",
"DDInter1609"
] | Ardeparin | Rivaroxaban | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
202,
25,
792
]
],
[
[
202,
21,
28703
],
[
28703,
60,
792
]
],
[
[
202,
24,
557
],
[
557,
24,
792
]
],
[
[
202,
24,
738
],
[
738,
... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ardeparin",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compoun... | Ardeparin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound)
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00186 | DB01233 | 905 | 1,311 | [
"DDInter1092",
"DDInter1197"
] | Lorazepam | Metoclopramide | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
905,
24,
1311
]
],
[
[
905,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
905,
24,
649
],
[
649,
63,
1311
]
],
[
[
905,
24,
662
],
[
662,
... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Lorazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is ... | Lorazepam (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Met... |
DB00450 | DB09082 | 78 | 659 | [
"DDInter603",
"DDInter1934"
] | Droperidol | Vilanterol | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
78,
24,
659
]
],
[
[
78,
25,
870
],
[
870,
23,
659
]
],
[
[
78,
25,
927
],
[
927,
63,
659
]
],
[
[
78,
25,
1069
],
[
1069,
24,
... | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludr... | Droperidol may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Droperidol may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a mod... |
DB00795 | DB01033 | 50 | 328 | [
"DDInter1725",
"DDInter1156"
] | Sulfasalazine | Mercaptopurine | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Moderate | 1 | [
[
[
50,
24,
328
]
],
[
[
50,
5,
11572
],
[
11572,
44,
328
]
],
[
[
50,
63,
663
],
[
663,
23,
328
]
],
[
[
50,
64,
126
],
[
126,
24,
... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) treats {v} (Disease)",
"Crohn's disease"
],
[
"Crohn's disease",
"{u} (Di... | Sulfasalazine (Compound) treats Crohn's disease (Disease) and Crohn's disease (Disease) is treated by Mercaptopurine (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when t... |
DB00427 | DB09117 | 1,233 | 957 | [
"DDInter1879",
"DDInter1391"
] | Triprolidine | Paraldehyde | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. ... | Moderate | 1 | [
[
[
1233,
24,
957
]
],
[
[
1233,
24,
1264
],
[
1264,
24,
957
]
],
[
[
1233,
63,
1594
],
[
1594,
24,
957
]
],
[
[
1233,
24,
1609
],
[
1609,... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylam... |
DB01004 | DB09331 | 563 | 745 | [
"DDInter806",
"DDInter478"
] | Ganciclovir | Daratumumab | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Moderate | 1 | [
[
[
563,
24,
745
]
],
[
[
563,
24,
4
],
[
4,
24,
745
]
],
[
[
563,
63,
597
],
[
597,
24,
745
]
],
[
[
563,
24,
810
],
[
810,
63,
... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinat... | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Ganciclovir may cause a moderate interaction that could exacerbate diseases when... |
DB00381 | DB14568 | 376 | 982 | [
"DDInter79",
"DDInter1000"
] | Amlodipine | Ivosidenib | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
376,
24,
982
]
],
[
[
376,
63,
1101
],
[
1101,
23,
982
]
],
[
[
376,
1,
1081
],
[
1081,
24,
982
]
],
[
[
376,
24,
770
],
[
770,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Amlodipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could... |
DB00835 | DB00909 | 100 | 306 | [
"DDInter245",
"DDInter1971"
] | Brompheniramine | Zonisamide | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Major | 2 | [
[
[
100,
25,
306
]
],
[
[
100,
6,
8374
],
[
8374,
45,
306
]
],
[
[
100,
24,
1609
],
[
1609,
63,
306
]
],
[
[
100,
63,
717
],
[
717,
... | [
[
[
"Brompheniramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zonisamide (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Br... |
DB00376 | DB01069 | 1,105 | 401 | [
"DDInter1870",
"DDInter1533"
] | Trihexyphenidyl | Promethazine | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1105,
24,
401
]
],
[
[
1105,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1105,
24,
104
],
[
104,
24,
401
]
],
[
[
1105,
6,
4304
],
[
4304,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine an... |
DB00682 | DB00827 | 126 | 646 | [
"DDInter1951",
"DDInter383"
] | Warfarin | Cinoxacin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Major | 2 | [
[
[
126,
25,
646
]
],
[
[
126,
23,
1053
],
[
1053,
62,
646
]
],
[
[
126,
24,
1532
],
[
1532,
62,
646
]
],
[
[
126,
64,
970
],
[
970,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cinoxacin"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide ... |
DB00374 | DB06589 | 1,061 | 1,250 | [
"DDInter1852",
"DDInter1400"
] | Treprostinil | Pazopanib | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1061,
24,
1250
]
],
[
[
1061,
7,
3681
],
[
3681,
45,
1250
]
],
[
[
1061,
7,
3553
],
[
3553,
46,
1250
]
],
[
[
1061,
18,
6983
],
[
6983... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Treprostinil",
"{u} (Compound) upregulates {v} (Gene)",
"FGFR3"
],
[
"FGFR3",
"{u} (Gene) is bound by {v} (Comp... | Treprostinil (Compound) upregulates FGFR3 (Gene) and FGFR3 (Gene) is bound by Pazopanib (Compound)
Treprostinil (Compound) upregulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Pazopanib (Compound)
Treprostinil (Compound) downregulates GLOD4 (Gene) and GLOD4 (Gene) is upregulated by Pazopanib (Compound)
Treprosti... |
DB11718 | DB11986 | 927 | 484 | [
"DDInter640",
"DDInter648"
] | Encorafenib | Entrectinib | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
927,
24,
484
]
],
[
[
927,
62,
1247
],
[
1247,
23,
484
]
],
[
[
927,
63,
1135
],
[
1135,
23,
484
]
],
[
[
927,
64,
1197
],
[
1197,
... | [
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Encorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Encorafenib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol ... |
DB00396 | DB08870 | 989 | 850 | [
"DDInter1529",
"DDInter228"
] | Progesterone | Brentuximab vedotin | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
989,
24,
850
]
],
[
[
989,
1,
443
],
[
443,
24,
850
]
],
[
[
989,
63,
245
],
[
245,
24,
850
]
],
[
[
989,
24,
159
],
[
159,
63,
... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u... | Progesterone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate... |
DB01069 | DB09291 | 401 | 741 | [
"DDInter1533",
"DDInter1615"
] | Promethazine | Rolapitant | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
401,
24,
741
]
],
[
[
401,
63,
211
],
[
211,
23,
741
]
],
[
[
401,
63,
506
],
[
506,
24,
741
]
],
[
[
401,
25,
924
],
[
924,
24,... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan ... |
DB01156 | DB01381 | 593 | 958 | [
"DDInter252",
"DDInter819"
] | Bupropion | Ginkgo biloba | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Moderate | 1 | [
[
[
593,
24,
958
]
],
[
[
593,
63,
1347
],
[
1347,
24,
958
]
],
[
[
593,
64,
1010
],
[
1010,
24,
958
]
],
[
[
593,
25,
129
],
[
129,
... | [
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
... | Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Bupropion may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cau... |
DB00005 | DB08870 | 1,057 | 850 | [
"DDInter687",
"DDInter228"
] | Etanercept | Brentuximab vedotin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Major | 2 | [
[
[
1057,
25,
850
]
],
[
[
1057,
24,
788
],
[
788,
24,
850
]
],
[
[
1057,
24,
496
],
[
496,
63,
850
]
],
[
[
1057,
25,
611
],
[
611,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Hepatiti... |
DB00023 | DB01211 | 305 | 609 | [
"DDInter127",
"DDInter393"
] | Asparaginase Escherichia coli | Clarithromycin | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
305,
24,
609
]
],
[
[
305,
24,
1570
],
[
1570,
24,
609
]
],
[
[
305,
24,
600
],
[
600,
23,
609
]
],
[
[
305,
25,
1101
],
[
1101,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wit... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate ... |
DB00754 | DB11988 | 157 | 270 | [
"DDInter696",
"DDInter1321"
] | Ethotoin | Ocrelizumab | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
157,
24,
270
]
],
[
[
157,
63,
134
],
[
134,
24,
270
]
],
[
[
157,
23,
1096
],
[
1096,
24,
270
]
],
[
[
157,
24,
281
],
[
281,
2... | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Ethotoin may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and My... |
DB01377 | DB06210 | 1,283 | 72 | [
"DDInter1119",
"DDInter631"
] | Magnesium oxide | Eltrombopag | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
1283,
24,
72
]
],
[
[
1283,
24,
286
],
[
286,
63,
72
]
],
[
[
1283,
24,
1596
],
[
1596,
24,
72
]
],
[
[
1283,
63,
14
],
[
14,
24... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydrox... | Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when tak... |
DB00209 | DB00211 | 352 | 1,290 | [
"DDInter1886",
"DDInter1213"
] | Trospium | Midodrine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Moderate | 1 | [
[
[
352,
24,
1290
]
],
[
[
352,
6,
12523
],
[
12523,
45,
1290
]
],
[
[
352,
21,
28929
],
[
28929,
60,
1290
]
],
[
[
352,
24,
752
],
[
752,... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midodrine"
]
],
[
[
"Trospium",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Trospium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Midodrine (Compound)
Trospium (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Midodrine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine ... |
DB09049 | DB12015 | 1,135 | 1,033 | [
"DDInter1261",
"DDInter53"
] | Naloxegol | Alpelisib | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Minor | 0 | [
[
[
1135,
23,
1033
]
],
[
[
1135,
63,
1335
],
[
1335,
24,
1033
]
],
[
[
1135,
64,
859
],
[
859,
24,
1033
]
],
[
[
1135,
25,
760
],
[
760,
... | [
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alpelisib"
]
],
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
... | Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naloxegol may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may... |
DB00990 | DB09381 | 1,547 | 192 | [
"DDInter705",
"DDInter678"
] | Exemestane | Esterified estrogens | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Moderate | 1 | [
[
[
1547,
24,
192
]
],
[
[
1547,
63,
1051
],
[
1051,
24,
192
]
],
[
[
1547,
24,
913
],
[
913,
63,
192
]
],
[
[
1547,
24,
1040
],
[
1040,
... | [
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide... | Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Exemestane may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00176 | DB06810 | 529 | 397 | [
"DDInter770",
"DDInter1484"
] | Fluvoxamine | Plicamycin | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
529,
24,
397
]
],
[
[
529,
24,
885
],
[
885,
24,
397
]
],
[
[
529,
24,
578
],
[
578,
63,
397
]
],
[
[
529,
25,
222
],
[
222,
24,... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and ... |
DB00163 | DB14491 | 1,461 | 428 | [
"DDInter1943",
"DDInter725"
] | Vitamin E | Ferrous fumarate | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1461,
24,
428
]
],
[
[
1461,
23,
1096
],
[
1096,
23,
428
]
],
[
[
1461,
24,
489
],
[
489,
24,
428
]
],
[
[
1461,
23,
1096
],
[
1096,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],... | Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Iron su... |
DB00771 | DB01142 | 262 | 1,264 | [
"DDInter397",
"DDInter593"
] | Clidinium | Doxepin | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
262,
24,
1264
]
],
[
[
262,
63,
508
],
[
508,
24,
1264
]
],
[
[
262,
24,
401
],
[
401,
24,
1264
]
],
[
[
262,
24,
1405
],
[
1405,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"P... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazin... |
DB00408 | DB09076 | 1,408 | 1,116 | [
"DDInter1099",
"DDInter1899"
] | Loxapine | Umeclidinium | An antipsychotic agent used in schizophrenia. [PubChem] | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
1408,
24,
1116
]
],
[
[
1408,
24,
849
],
[
849,
24,
1116
]
],
[
[
1408,
1,
695
],
[
695,
24,
1116
]
],
[
[
1408,
63,
128
],
[
128,
... | [
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
... | Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Loxapine (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exa... |
DB00191 | DB08882 | 73 | 1,281 | [
"DDInter1447",
"DDInter1070"
] | Phentermine | Linagliptin | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
73,
24,
1281
]
],
[
[
73,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
73,
21,
28762
],
[
28762,
60,
1281
]
],
[
[
73,
36,
1529
],
[
1529,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Phentermine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Linagliptin (Compound)
Phentermine (Compound) resembles Metamfeta... |
DB00748 | DB11601 | 662 | 1,270 | [
"DDInter297",
"DDInter1889"
] | Carbinoxamine | Tuberculin purified protein derivative | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
662,
24,
1270
]
],
[
[
662,
63,
13
],
[
13,
24,
1270
]
],
[
[
662,
24,
1053
],
[
1053,
24,
1270
]
],
[
[
662,
35,
1376
],
[
1376,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Carbinoxamine may cause a moderate interaction that could exacerbate dise... |
DB00196 | DB00647 | 600 | 675 | [
"DDInter743",
"DDInter528"
] | Fluconazole | Dextropropoxyphene | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Moderate | 1 | [
[
[
600,
24,
675
]
],
[
[
600,
24,
888
],
[
888,
64,
675
]
],
[
[
600,
25,
494
],
[
494,
1,
675
]
],
[
[
600,
23,
307
],
[
307,
1,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene
Fluconazole may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) re... |
DB00531 | DB06209 | 450 | 256 | [
"DDInter456",
"DDInter1508"
] | Cyclophosphamide | Prasugrel | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Minor | 0 | [
[
[
450,
23,
256
]
],
[
[
450,
6,
10215
],
[
10215,
45,
256
]
],
[
[
450,
21,
28681
],
[
28681,
60,
256
]
],
[
[
450,
24,
593
],
[
593,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (... | Cyclophosphamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Cyclophosphamide (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases whe... |
DB00802 | DB11718 | 1,322 | 927 | [
"DDInter43",
"DDInter640"
] | Alfentanil | Encorafenib | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1322,
24,
927
]
],
[
[
1322,
63,
1324
],
[
1324,
24,
927
]
],
[
[
1322,
24,
1264
],
[
1264,
24,
927
]
],
[
[
1322,
24,
484
],
[
484,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxe... |
DB11003 | DB12267 | 748 | 1,476 | [
"DDInter100",
"DDInter233"
] | Anthrax vaccine | Brigatinib | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
748,
24,
1476
]
],
[
[
748,
63,
168
],
[
168,
23,
1476
]
],
[
[
748,
63,
629
],
[
629,
24,
1476
]
],
[
[
748,
24,
1456
],
[
1456,
... | [
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
]... | Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.